Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 4/20 | 0.47 |
| ▸ | ACACA | Q13085 | 4/20 | 0.47 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329790 | 0.92 | PIM1 (0.55) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3329739 | 0.92 | PIM1 (0.53) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3330323 | 0.91 | PIM1 (0.63) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3330418 | 0.91 | PIM1 (0.63) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3328243 | 0.90 | PIM1 (0.64) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3327369 | 0.89 | PIM1 (0.61) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3329321 | 0.89 | PIM1 (0.60) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3329788 | 0.88 | PIM1 (0.61) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3331845 | 0.87 | PIM1 (0.60) | PIM1CDC7CSNK2A2CLK1GSK3B | |
| SCHEMBL3330930 | 0.86 | PIM1 (0.57) | PIM1CDC7CSNK2A2CLK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | claimed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2008133955-A1 | 6-PHENYLPYRIMIDINONES AS PIM MODULATORS | EXELIXIS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | PIM1 1/4885CDC7 3813/4885CSNK2A2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.